Inaktiver Wert

Andere Sprachen Allarity Therapeutics, Inc. Nasdaq Stockholm

Aktien

A3C8U3

US0167441049

ALLR

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement	14:00
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances	14.05.
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock	07.05.
Allarity Therapeutics Says Stockholders' Equity 'Significantly' Exceeds Nasdaq's $2.5 Million Minimum Rule	06.05.
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1	06.05.
Wall Street Set to Open Higher Thursday After Fed Holds Rate Steady, Jobless Claims Lower Than Expected	02.05.
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer	02.05.
Allarity Therapeutics, Inc. Announces Early Discontinuation of Its Phase 2 Clinical Trial of Stenoparib	02.05.
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement	29.04.
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)	17.04.
Top Premarket Gainers	15.04.
Top Premarket Gainers	12.04.
Allarity Therapeutics to Implement 1-for-20 Reverse Stock Split	04.04.
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split	04.04.
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer	27.03.
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer	27.03.
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)	25.03.
Allarity Therapeutics : Material Agreement - Form 8-K	20.03.
Allarity Therapeutics, Inc. announced that it has received $0.6 million in funding	14.03.
Allarity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Allarity Therapeutics, Inc. Nasdaq Stockholm

Aktien

A3C8U3

US0167441049

ALLR

Andere Sprachen

Filter